US pharma giant is unhappy with Germany; CEO calls planned healthcare reform ‘terrible’

US drug maker Eli Lilly is cutting its investment in a German factory by half. This decision follows new healthcare cost-cutting laws in Germany. The company CEO called the reforms a bad signal for the industry. This move impacts Germany’s industrial plans. The factory will now operate at reduced capacity with fewer jobs. Other companies are also reconsidering local investments.